Conference Objectives: Discuss the evolving role and advancements in the fields of autologous and allogeneic hematopoietic stem cell transplantation (HSCT) and cellular therapeutics. Discuss the advancements of alternative donor transplantation. Discuss the importance of risk stratification in treatment decisions for patients with acute and chronic leukemia, lymphoma, multiple myeloma and bone marrow failure syndromes. Evaluate the relative importance of age, disease status, cytogenetics and molecular markers as prognostic and predictive factors for patients with hematologic malignancies. Articulate the influence of HLA-typing at diagnosis and the timing of HSCT on posttransplant outcomes. Discuss and assess treatment options and strategies for patients who are over 60 years of age. Discuss and assess optimal treatment strategies and supportive care in the posttransplant phase. Review and discuss the latest clinical trials and novel therapies available for patients with hematologic malignancies and bone marrow failure syndromes.

MRIGlobal will host a luncheon featuring Bill Nye The Science Guy celebrating those who have supported our science over the past 75 years.